Author + information
- Günther Silbernagel,
- Hubert Scharnagl,
- Marcus Kleber,
- Tatjana Stojakovic and
- Winfried März
Background: It is unclear whether proprotein convertase subtilisin-kexin type 9 (PCSK9) concentrations may be useful for cardiovascular risk stratification.
Methods: The LUdwigshafen RIsk and Cardiovascular health (LURIC) study is a prospective observational registry of patients who were referred for coronary angiography. Circulating PCSK9 was measured in 2,139 participants of the LURIC study. There was a follow-up for all-cause and cardiovascular mortality with a median (interquartile range) duration of 10.1 (8.1-10.8) years.
Results: The mean (standard deviation) age of the participants (1470 males and 669 females) was 62.6 (10.8) years, body mass index 27.3 (4.0) kg/m2, and low density lipoprotein cholesterol 114 (33) mg/dl. The mean (standard deviation) PCSK9 concentration was 220 (82) ng/ml. 1,035 (48.4 %) participants were on statins. Use of statins was associated with significantly lower low density lipoprotein cholesterol (106 vs. 121 mg/dl, p<0.001) but significantly higher circulating PCSK9 (244 vs. 197 mg/dl, p<0.001). A total of 674 (31.5 %) study participants died from any cause and 431 (20.1 %) from cardiovascular diseases. Tertiles of PCSK9 were not associated with the risk of death from any cause (3rd vs. 1st tertile, hazard ratio 1.09, 95% confidence interval 0.91-1.31, P=0.367) and from cardiovascular diseases (3rd vs. 1st tertile: hazard ratio 1.09, 95% confidence interval 0.86-1.37, P=0.476).
Conclusions: PCSK9 may be upregulated by statin use and does not appear to be useful for cardiovascular risk stratification.
Moderated Poster Contributions
Prevention Moderated Poster Theater, Poster Hall, Hall C
Friday, March 17, 2017, 11:00 a.m.-11:10 a.m.
Session Title: The PCSK9 Revolution: New Insights Into Evaluation and Treatment
Abstract Category: 32. Prevention: Clinical
Presentation Number: 1133M-11
- 2017 American College of Cardiology Foundation